BioSpace News Archive

Abcam plc, and, a global leader in the supply of life science research tools, provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM, as originally announced on 17 October 2022.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1/2 clinical trial to evaluate IDE161, a small molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG), for the treatment of patients having solid tumors with homologous recombination deficiency (HRD).

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has granted an exclusive license to Ocular Therapeutix Inc. (“Ocular”) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States.

Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is offering to sell, subject to market and other conditions, shares of its common stock and shares of its Series A convertible preferred stock.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”).

Ellipses Pharma Limited has presented preliminary data from the first in human phase 1/2 trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana.

JW Therapeutics presented the latest clinical data on Carteyva® in Chinese adults with relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma at the 64th American Society of Hematology Annual Meeting.

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022.

Castellum, Inc. (NYSE-American: CTM) is pleased to announce that it is one of the winners of the Architecture and Integration Directorate Multiple Award Indefinite Delivery/Indefinite Quantity Contract (AFLCMC/XA) (MAC IDIQ) contract.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).